A prospective multicentre experience of early administration of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies (MA) with efficacy among patients with hematological malignancies and early-stage COVID- 19 was reported by Weinbergerová et al. The study validated the safety and efficacy of MA early use among hematological patients with newly diagnosed early-stage COVID-19 in terms of alleviating infection course and decreasing mortality. However no reference to new variant (Delta and Omicron) or other MA (e.g., Sotrovimab) has been reported. We reported our monocentric experience of 8 aggressive lymphoma patients with Omicron infection, 7 of whom treated with this MA in our Institution between December 2021 and February 2022. Among the patients treated with Sotrovimab nobody experienced neither SARS-CoV2 reactivation, nor other infectious events. One patients on active lymphoma treatment was hospitalized for pneumonia and treated with remdesivir. In 4/8 patients negativization of molecular swab occurred concomitantly to symptoms resolution with a median of 5.25 days, while the other 4 patients remained persistently positive with a median of 26.3 days. In this group, in order to maintain the chemo/chemoimmunotherapy (CT/CIT) dose-density, lymphoma treatment was reassumed independently on molecular swab analysis. SARS-CoV-2 negativization occurred with a median of 7.7 days after the resumption of CT/CIT. The one patient treated with remdesivir, although still positive to molecular swab, restarted R-COMP regimen at symptoms resolution too, but experienced an Omicron pneumonia exacerbation. This is the first case series reported in literature of patients affected by Omicron variant in which Sotrovimab seems to provide a resolution of COVID-19 disease, even in patient with molecular swab positive persistence too. Patients with aggressive lymphoma histologies should not be deprived of the best available treatment of their disease after sotrovimab administration, even in the presence of a still positive Omicron swab.

Hematology Unit Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan Italy

Infectious Diseases Unit Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy

Università degli Studi di Milano Milan Italy

Hematol Oncol. 2024 May;42(3):e3267. doi: 10.1002/hon.3267. PubMed

Zobrazit více v PubMed

Weinbergerová B, Demel I, Víšek B. Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients—a Czech multicenter experience. Hematol Oncol. 2022;40(2):280‐286. PubMed PMC

World Health Organization . Coronavirus Disease (COVID‐19) Pandemic. 2020. https://www.who.int/emergencies/diseases/novel‐coronavirus‐2019

Visco C, Marcheselli L, Mina R, et al. A prognostic model for patients with lymphoma and COVID‐19: a multicentre cohort study. Blood Adv. 2022;6(1):327‐338. 10.1182/bloodadvances.2021005691 PubMed DOI PMC

Garciá‐Suárez J, de La Cruz J, Cedillo Á, et al. Impact of hematologic malignancy and type of cancer therapy on COVID‐19 severity and mortality: lessons from a large population‐based registry study. J Hematol Oncol. 2020;13(1):133. 10.1186/s13045-020-00970-7 PubMed DOI PMC

Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID‐19 severity in patients with hematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020;7(10):e737‐e745. 10.1016/s2352-3026(20)30251-9 PubMed DOI PMC

Marasco V, Carniti C, Guidetti A, et al. T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. Br J Haematol. 2022;196(3):548‐558. 10.1111/bjh.17877 PubMed DOI PMC

Passamonti F, Romano A, Salvini M, et al. COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies. Br J Haematol. 2021;195(3):371‐377. 10.1111/bjh.17704 PubMed DOI PMC

Weinreich DM, Sivapalasingam S, Norton T, et al. REGN‐COV2, a neutralizing antibody cocktail, in outpatients with Covid‐19. N Engl J Med. 2021;384(3):238‐251. 10.1056/nejmoa2035002 PubMed DOI PMC

Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid‐19. N Engl J Med. 2021;385(15):1382‐1392. 10.1056/nejmoa2102685 PubMed DOI PMC

Petersen E, Ntoumi F, Hui DS, et al. Emergence of new SARS‐CoV‐2 Variant of Concern Omicron (B.1.1.529)—a highlights Africa’s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID‐19 response and control efforts. Int J Infect Dis. 2022;114:268‐272. 10.1016/j.ijid.2021.11.040 PubMed DOI PMC

Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody‐mediated neutralization: implications for control of the COVID‐19 pandemic. Cell. 2022;185(3):447‐456. e11. 10.1016/j.cell.2021.12.032 PubMed DOI PMC

Lee M, Quinn R, Pradhan K, et al. Impact of COVID‐19 on case fatality rate of patients with cancer during the Omicron wave. Cancer Cell. 2022;40(4):343‐345. 10.1016/j.ccell.2022.02.012 PubMed DOI PMC

Gupta A, Gonzalez‐Rojas Y, Juarez E, et al. Early treatment for covid‐19 with SARS‐CoV‐2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941‐1950. 10.1056/nejmoa2107934 PubMed DOI

Drożdżal S, Rosik J, Lechowicz K, et al. An update on drugs with therapeutic potential for SARS‐CoV‐2 (COVID‐19) treatment. Drug Resist Updates. 2021;59:100794. 10.1016/j.drup.2021.100794 PubMed DOI PMC

Gaitzsch E, Passerini V, Khatamzas E, et al. COVID‐19 in patients receiving CD20‐depleting immunochemotherapy for B‐cell lymphoma. Hemasphere. 2021;5(7):e603. 10.1097/hs9.0000000000000603 PubMed DOI PMC

van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease‐2019 (COVID‐19). Nat Commun. 2021;12(1):267. 10.1038/s41467-020-20568-4 PubMed DOI PMC

Buske C, Dreyling M, Alvarez‐Larrán A, et al. Managing hematological cancer patients during the COVID‐19 pandemic: an ESMO‐EHA Interdisciplinary Expert Consensus. ESMO Open. 2022;7(2):100403. 10.1016/j.esmoop.2022.100403 PubMed DOI PMC

Taha Y, Wardle H, Evans AB, et al. Persistent SARS‐CoV‐2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN‐COV2) monoclonal antibody therapy. Ann Clin Microbiol Antimicrob. 2021;20(1):85. 10.1186/s12941-021-00491-2 PubMed DOI PMC